Praxis Precision Medicines, Inc. (PRAX)
Data as of , from SEC Form 4 filings.
See up to 3 months of PRAX. The 7-day demo opens the 1M and 3M ranges and puts PRAX on your watchlist.
Start 7-day demoData as of , from SEC Form 4 filings.
See up to 3 months of PRAX. The 7-day demo opens the 1M and 3M ranges and puts PRAX on your watchlist.
Start 7-day demo
Jill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorPraxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
https://www.praxismedicines.comSEC filings for PRAX on EDGAR
No Form 4 activity for PRAX in the last 90 days.
28 Form 4 filings on record, the earliest from Nov 15, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Marcio Souza - Officer | Gift | Common Stock | 20,521 | $0.00 | - | |
| Marcio Souza - Officer | Gift | Common Stock | 2,600 | $0.00 | - | |
| Jill Desimone - Director | Open-market sale | Common Stock | 2,854 | $311.91 footnote F8 | $890K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,004 | $312.83 footnote F9 | $314K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 504 | $313.66 footnote F10 | $158K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,279 | $314.90 footnote F11 | $403K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 837 | $315.71 footnote F12 | $264K | |
| Jill Desimone - Director | Option exercise | Stock Option (Right to Buy) | 8,566 | $0.00 | - | |
| Jill Desimone - Director | Option exercise | Stock Option (Right to Buy) | 3,034 | $0.00 | - | |
| Jill Desimone - Director | Option exercise | Common Stock | 8,566 | $44.25 | $379K | |
| Jill Desimone - Director | Option exercise | Common Stock | 3,034 | $147.30 | $447K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 10 | $301.44 | $3K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 120 | $303.13 footnote F2 | $36K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 320 | $305.31 footnote F3 | $98K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 683 | $306.77 footnote F4 | $210K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,240 | $308.24 footnote F5 | $382K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 999 | $309.38 footnote F6 | $309K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,750 | $310.89 footnote F7 | $544K | |
| ||||||
| Stuart A. Arbuckle - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Stuart A. Arbuckle - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
 Jeffrey Chodakewitz - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Jeffrey Chodakewitz - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| William D. Young - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| William D. Young - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Jill Desimone - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Jill Desimone - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Merit Ester Cudkowicz - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Merit Ester Cudkowicz - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Dean J. Mitchell - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Dean J. Mitchell - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
 Jeffrey B. Kindler - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Gregory Norden - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Gregory Norden - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Lauren Mastrocola - Officer | Grant or award | Common Stock | 127 | $167.94 | $21K | |
| Alex Nemiroff - Officer | Grant or award | Common Stock | 78 | $167.94 | $13K | |
| Timothy Edwin Kelly - Officer | Grant or award | Common Stock | 121 | $167.94 | $20K | |
 Megan Sniecinski - Officer | Grant or award | Common Stock | 89 | $167.94 | $15K | |
| Marcio Souza - Officer | Grant or award | Common Stock | 126 | $167.94 | $21K | |
| Stuart A. Arbuckle - Director | Grant or award | Common Stock | 688 | $0.00 | - | |
| Stuart A. Arbuckle - Director | Grant or award | Common Stock | 478 | $0.00 | - | |
| Stuart A. Arbuckle - Director | Grant or award | Stock Option (Right to Buy) | 224 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Common Stock | 688 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Common Stock | 478 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Stock Option (Right to Buy) | 224 | $0.00 | - | |
| Timothy Edwin Kelly - Officer | Grant or award | Common Stock | 384 | $31.62 | $12K | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 1,714 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 6,230 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 5,652 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 9,100 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 1,714 | $83.85 | $144K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 6,230 | $133.65 | $833K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 2,434 | $44.40 | $108K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 5,652 | $44.40 | $251K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 9,100 | $56.94 | $518K | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 9,100 | $194.30 | $1.77M | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 1,714 | $190.86 footnote F1 | $327K | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 13,339 | $192.53 footnote F2 | $2.57M | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 977 | $193.23 footnote F3 | $189K | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 2,434 | $0.00 | - | |
| ||||||
| Lauren Mastrocola - Officer | Open-market sale | Common Stock | 2,145 | $192.71 footnote F2 | $413K | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 1,047 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 508 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 1,557 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 2,680 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 2,351 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 5,250 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 1,047 | $49.50 | $52K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 508 | $83.85 | $43K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 1,557 | $133.65 | $208K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 2,680 | $43.37 | $116K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 207 | $44.40 | $9K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 2,351 | $44.40 | $104K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 5,250 | $56.94 | $299K | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 207 | $0.00 | - | |
| Lauren Mastrocola - Officer | Open-market sale | Common Stock | 11,455 | $191.96 footnote F1 | $2.20M | |
| ||||||
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 447 | $91.04 footnote F4 | $41K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 487 | $131.64 footnote F9 | $64K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 308 | $132.19 footnote F10 | $41K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 1,363 | $92.03 footnote F5 | $125K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 559 | $100.11 footnote F6 | $56K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 27,287 | $101.00 | $2.76M | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 250,000 | $104.31 footnote F7 | $26.08M | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 1,661 | $130.10 footnote F8 | $216K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 19,198 | $140.00 footnote F11 | $2.69M | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock, $0.0001 par value per share ("Common Stock") | 12,600 | $90.00 footnote F3 | $1.13M | |
| ||||||
| Dean J. Mitchell - Director | Option exercise | Common Stock | 1,932 | $14.36 | $28K | |
| Dean J. Mitchell - Director | Option exercise | Common Stock | 8,566 | $44.25 | $379K | |
| Dean J. Mitchell - Director | Option exercise | Common Stock | 1,753 | $44.04 | $77K | |
| Dean J. Mitchell - Director | Option exercise | Stock Option (Right to Buy) | 1,932 | $0.00 | - | |
| Dean J. Mitchell - Director | Option exercise | Stock Option (Right to Buy) | 8,566 | $0.00 | - | |
| Dean J. Mitchell - Director | Option exercise | Stock Option (Right to Buy) | 1,753 | $0.00 | - | |
| William D. Young - Director | Grant or award | Stock Option (Right to Buy) | 10,520 | $0.00 | - | |
| Dean J. Mitchell - Director | Grant or award | Stock Option (Right to Buy) | 10,520 | $0.00 | - | |
| Lauren Mastrocola - Officer | Grant or award | Common Stock | 294 | $37.40 | $11K | |
| Timothy Edwin Kelly - Officer | Grant or award | Common Stock | 205 | $37.40 | $8K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 7,583 | $56.94 | $432K | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 8,239 | $80.20 | $661K | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 7,583 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 4,374 | $56.94 | $249K | |
| Lauren Mastrocola - Officer | Open-market sale | Common Stock | 5,188 | $81.78 | $424K | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 4,374 | $0.00 | - | |
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Stock trades in PRAX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.Democrat, CA-31 | Purchase | $1,001 to $15,000 | Member | 13 days | Original filing | ||
| Gilbert Ray Cisneros, Jr.Democrat, CA-31 | Purchase | $1,001 to $15,000 | Member | 36 days | Original filing |
House of Representatives Periodic Transaction Reports from 2024. Senate filings are not included yet. The full history of PRAX beside its insider purchases is in the Congress Tracker.
Praxis Precision Medicines, Inc. (PRAX) has filed no insider reports in the last 90 days. The most recent on record is dated 8 July 2026. The full record for PRAX runs to 28 Form 4 filings, the earliest from 15 November 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
No insider purchases of PRAX were filed in the last 90 days.
No insider sales of PRAX were filed in the last 90 days. 30 sales are on record for this company.
This page collects PRAX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
